Microscopic colitis (MC) is an inflammatory disease of the large intestine associated with urgent watery diarrhoea. MC may occur in people of all ages, although the disease primarily affects older women. Once believed to be rare, MC is now known to be a common cause of chronic watery diarrhoea in high-income countries, affecting 1 in 115 women and 1 in 286 men during their lifetime in Swedish population-based estimates. An inappropriate immune response to disturbances in the gut microenvironment is implicated in the pathogenesis of MC. Evidence also supports an underlying genetic basis for disease. The diagnosis of MC relies on clinical symptoms and microscopic assessment of colonic biopsy samples. MC is categorized histologically into collagenous colitis, lymphocytic colitis and their incomplete forms. The mainstay of treatment includes the use of budesonide, with or without adjunctive therapies, and withdrawal of offending drugs. Emerging studies suggest a role for biologicals and immunosuppressive therapies for the management of budesonide-refractory or budesonide-dependent disease. MC can have a substantial negative effect on patient quality of life. The outlook for MC includes a better understanding of the immune response, genetics and the microbiome in disease pathogenesis along with progress in disease management through robust clinical trials.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 1 digital issues and online access to articles
$99.00 per year
only $99.00 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Bai, S., Siegal, G. P. & Jhala, N. C. Foxp3 expression patterns in microscopic colitides: a clinicopathologic study of 69 patients. Am. J. Clin. Pathol. 137, 931–936 (2012).
Carrasco, A. et al. Immunological differences between lymphocytic and collagenous colitis. J. Crohns Colitis 10, 1055–1066 (2016).
Weimers, P. et al. Incidence and prevalence of microscopic colitis between 2001 and 2016: a Danish nationwide cohort study. J. Crohns Colitis https://doi.org/10.1093/ecco-jcc/jjaa108 (2020).
Windon, A. L. et al. Lymphocytic and collagenous colitis in children and adolescents: comprehensive clinicopathologic analysis with long-term follow up. Hum. Pathol. 106, 13–22 (2020).
Mellander, M. R. et al. Microscopic colitis: a descriptive clinical cohort study of 795 patients with collagenous and lymphocytic colitis. Scand. J. Gastroenterol. 51, 556–562 (2016).
Pardi, D. S. & Kelly, C. P. Microscopic colitis. Gastroenterology 140, 1155–1165 (2011).
Verhaegh, B. P. M. et al. Course of disease in patients with microscopic colitis — a European prospective incident cohort study. J. Crohns Colitis https://doi.org/10.1093/ecco-jcc/jjab007 (2021).
Bjornbak, C., Engel, P. J., Nielsen, P. L. & Munck, L. K. Microscopic colitis: clinical findings, topography and persistence of histopathological subgroups. Alimen. Pharmacol. Ther. 34, 1225–1234 (2011).
Nyhlin, N., Wickbom, A., Montgomery, S. M., Tysk, C. & Bohr, J. Long-term prognosis of clinical symptoms and health-related quality of life in microscopic colitis: a case-control study. Alimen. Pharmacol. Ther. 39, 963–972 (2014).
Langner, C. et al. Histology of microscopic colitis-review with a practical approach for pathologists. Histopathology 66, 613–626 (2015). This paper is a comprehensive review of the histological findings in MC.
Engel, P. J. H., Fiehn, A. K., Munck, L. K. & Kristensson, M. The subtypes of microscopic colitis from a pathologist’s perspective: past, present and future. Ann. Transl Med. 6, 69 (2018).
Lindstrom, C. G. ‘Collagenous colitis’ with watery diarrhoea–a new entity? Pathol. Eur. 11, 87–89 (1976).
Read, N. W. et al. Chronic diarrhea of unknown origin. Gastroenterology 78, 264–271 (1980).
Bonderup, O. K., Wigh, T., Nielsen, G. L., Pedersen, L. & Fenger-Gron, M. The epidemiology of microscopic colitis: a 10-year pathology-based nationwide Danish cohort study. Scand. J. Gastroenterol. 50, 393–398 (2015).
Bergman, D. et al. A nationwide cohort study of the incidence of microscopic colitis in Sweden. Alimen. Pharmacol. Ther. 49, 1395–1400 (2019). A nationwide cohort study demonstrating the incidence of MC by calendar year, sex and disease subtype. This study provides the most recent estimates of the lifetime prevalence of the disease.
Verhaegh, B. P. et al. Incidence of microscopic colitis in the Netherlands. A nationwide population-based study from 2000 to 2012. Dig. Liver Dis. 47, 30–36 (2015).
Pardi, D. S. et al. The epidemiology of microscopic colitis: a population based study in Olmsted County, Minnesota. Gut 56, 504–508 (2007).
Fernandez-Banares, F. et al. Incidence of collagenous and lymphocytic colitis: a 5-year population-based study. Am. J. Gastroenterol. 94, 418–423 (1999).
Fernandez-Banares, F. et al. Evolution of the incidence of collagenous colitis and lymphocytic colitis in Terrassa, Spain: a population-based study. Inflamm. Bowel Dis. 17, 1015–1020 (2011).
Fumery, M. et al. Incidence, clinical presentation, and associated factors of microscopic colitis in Northern France: a population-based study. Dig. Dis. Sci. 62, 1571–1579 (2017).
Gentile, N. M. et al. The epidemiology of microscopic colitis in Olmsted County from 2002 to 2010: a population-based study. Clin. Gastroenterol. Hepatol. 12, 838–842 (2014).
Kane, J. S., Rotimi, O. & Ford, A. C. Macroscopic findings, incidence and characteristics of microscopic colitis in a large cohort of patients from the United Kingdom. Scand. J. Gastroenterol. 52, 988–994 (2017).
Agnarsdottir, M. et al. Collagenous and lymphocytic colitis in Iceland. Dig. Dis. Sci. 47, 1122–1128 (2002).
Miehlke, S. et al. European guidelines on microscopic colitis: United European Gastroenterology (UEG) and European Microscopic Colitis Group (EMCG) statements and recommendations. United European Gastroenterol. J. https://doi.org/10.1177/2050640620951905 (2021). This paper describes the European guidelines for diagnosis and management of MC.
Burke, K. E. et al. Smoking is associated with an increased risk of microscopic colitis: results from two large prospective cohort studies of US Women. J. Crohns Colitis 12, 559–567 (2018).
Davidson, S. et al. Microscopic colitis in Denmark and Sweden: incidence, putative risk factors, histological assessment and endoscopic activity. Scand. J. Gastroenterol. 53, 818–824 (2018).
Gado, A. S., Ebeid, B. A., El Hindawi, A. A., Akl, M. M. & Axon, A. T. Prevalence of microscopic colitis in patients with chronic diarrhea in Egypt: a single-center study. Saudi J. Gastroenterol. 17, 383–386 (2011).
Valle Mansilla, J. L., Leon Barua, R., Recavarren Arce, S., Berendson Seminario, R. & Biber Poillevard, M. Microscopic colitis in patients with chronic diarrhea. Rev. Gastroenterol. Peru 22, 275–278 (2002).
Essid, M., Kallel, S., Ben Brahim, E., Chatti, S. & Azzouz, M. M. Prevalence of the microscopic colitis to the course of the chronic diarrhea: about 150 cases. Tunis. Med. 83, 284–287 (2005).
Erdem, L. et al. Prevalence of microscopic colitis in patients with diarrhea of unknown etiology in Turkey. World J. Gastroenterol. 14, 4319–4323 (2008).
Olesen, M., Eriksson, S., Bohr, J., Jarnerot, G. & Tysk, C. Microscopic colitis: a common diarrhoeal disease. An epidemiological study in Orebro, Sweden, 1993-1998. Gut 53, 346–350 (2004).
Verhaegh, B. P. et al. High risk of drug-induced microscopic colitis with concomitant use of NSAIDs and proton pump inhibitors. Aliment. Pharmacol. Ther. 43, 1004–1013 (2016).
Masclee, G. M., Coloma, P. M., Kuipers, E. J. & Sturkenboom, M. C. Increased risk of microscopic colitis with use of proton pump inhibitors and non-steroidal anti-inflammatory drugs. Am. J. Gastroenterol. 110, 749–759 (2015).
Bonderup, O. K., Fenger-Gron, M., Wigh, T., Pedersen, L. & Nielsen, G. L. Drug exposure and risk of microscopic colitis: a nationwide Danish case-control study with 5751 cases. Inflamm. Bowel Dis. 20, 1702–1707 (2014).
Fernandez-Banares, F. et al. Drug consumption and the risk of microscopic colitis. Am. J. Gastroenterol. 102, 324–330 (2007).
Bhatt, A. P. et al. Nonsteroidal anti-inflammatory drug-induced leaky gut modeled using polarized monolayers of primary human intestinal epithelial cells. ACS Infect. Dis. 4, 46–52 (2018).
Berg, D. J. et al. Rapid development of colitis in NSAID-treated IL-10-deficient mice. Gastroenterology 123, 1527–1542 (2002).
Ligumsky, M., Simon, P. L., Karmeli, F. & Rachmilewitz, D. Role of interleukin 1 in inflammatory bowel disease-enhanced production during active disease. Gut 31, 686–689 (1990).
Burke, K. E. et al. Identification of menopausal and reproductive risk factors for microscopic colitis — results from the nurses’ health study. Gastroenterology 155, 1764–1775.e2 (2018). This paper is a large prospective cohort study demonstrating a novel association between menopausal hormone therapy and oral contraceptive use and the risk of MC. This study also verifies independent associations of other medications and the risk of MC.
Law, E. H. et al. Association between proton pump inhibitors and microscopic colitis. Ann. Pharmacother. 51, 253–263 (2017).
Bonderup, O. K., Nielsen, G. L., Dall, M., Pottegard, A. & Hallas, J. Significant association between the use of different proton pump inhibitors and microscopic colitis: a nationwide Danish case-control study. Aliment. Pharmacol. Ther. 48, 618–625 (2018).
Umeno, J. et al. Letter: lansoprazole consumption is more common in Japanese patients with collagenous colitis. Aliment. Pharmacol. Ther. 38, 208–209 (2013).
Nomura, E. et al. Linear mucosal defects: a characteristic endoscopic finding of lansoprazole-associated collagenous colitis. Endoscopy 42 (Suppl. 2), E9–E10 (2010).
Wilcox, G. M. & Mattia, A. R. Microscopic colitis associated with omeprazole and esomeprazole exposure. J. Clin. Gastroenterol. 43, 551–553 (2009).
Keszthelyi, D. et al. Proton pump inhibitor use is associated with an increased risk for microscopic colitis: a case-control study. Aliment. Pharmacol. Ther. 32, 1124–1128 (2010).
Alpizar-Rodriguez, D. et al. Female hormonal factors and the development of anti-citrullinated protein antibodies in women at risk of rheumatoid arthritis. Rheumatology 56, 1579–1585 (2017).
Khalili, H. et al. Hormone therapy increases risk of ulcerative colitis but not Crohn’s disease. Gastroenterology 143, 1199–1206 (2012).
Khalili, H. et al. Oral contraceptives, reproductive factors and risk of inflammatory bowel disease. Gut 62, 1153–1159 (2013).
Roth, B., Manjer, J. & Ohlsson, B. Microscopic colitis and reproductive factors related to exposure to estrogens and progesterone. Drug Target Insights 7, 53–62 (2013).
Pai, R. K. et al. The significance of histological activity measurements in immune checkpoint inhibitor colitis. Aliment. Pharmacol. Ther. 53, 150–159 (2021). This paper describes MC induced by checkpoint inhibitors, a complication that will be increasingly observed with the growing use of these agents in cancer therapy.
Ibraheim, H., Green, M., Papa, S. & Powell, N. Topical beclometasone dipropionate in the management of immune checkpoint inhibitor-induced microscopic colitis. BMJ Case Rep. 12, e226481 (2019).
Hughes, M. S. et al. Budesonide treatment for microscopic colitis from immune checkpoint inhibitors. J. Immunother. Cancer 7, 292 (2019).
Fernandez-Banares, F. et al. Collagenous and lymphocytic colitis. evaluation of clinical and histological features, response to treatment, and long-term follow-up. Am. J. Gastroenterol. 98, 340–347 (2003).
Rosa, I. et al. Ticlopidine-induced lymphocytic colitis [In French]. Ann. Med. Interne 150, 437–439 (1999).
Martinez Aviles, P., Gisbert Moya, C., Berbegal Serra, J. & Lopez Benito, I. Ticlopidine-induced lymphocytic colitis. Med. Clin. 106, 317 (1996).
Hoffman, H. S. & Butensky, M. S. Severe diarrhea with Ticlid therapy. Conn. Med. 58, 251 (1994).
Berrebi, D. et al. Ticlopidine induced colitis: a histopathological study including apoptosis. J. Clin. Pathol. 51, 280–283 (1998).
Fernandez-Banares, F. et al. Epidemiological risk factors in microscopic colitis: a prospective case-control study. Inflamm. Bowel Dis. 19, 411–417 (2013).
Yen, E. F. et al. Current and past cigarette smoking significantly increase risk for microscopic colitis. Inflamm. Bowel Dis. 18, 1835–1841 (2012).
Wickbom, A., Nyhlin, N., Montgomery, S. M., Bohr, J. & Tysk, C. Family history, comorbidity, smoking and other risk factors in microscopic colitis: a case-control study. Eur. J. Gastroenterol. Hepatol. 29, 587–594 (2017).
Verhaegh, B. P. M. et al. Early life exposure, lifestyle, and comorbidity as risk factors for microscopic colitis: a case-control study. Inflamm. Bowel Dis. 23, 1040–1046 (2017).
Roth, B., Gustafsson, R. J., Jeppsson, B., Manjer, J. & Ohlsson, B. Smoking- and alcohol habits in relation to the clinical picture of women with microscopic colitis compared to controls. BMC Women’s Health 14, 16 (2014).
Vigren, L. et al. Is smoking a risk factor for collagenous colitis? Scand. J. Gastroenterol. 46, 1334–1339 (2011).
Burke, K. E. et al. Smoking is associated with an increased risk of microscopic colitis: results from two large prospective cohort studies of US women. J. Crohns Colitis 12, 559–567 (2018).
Baert, F. et al. Lymphocytic colitis: a distinct clinical entity? A clinicopathological confrontation of lymphocytic and collagenous colitis. Gut 45, 375–381 (1999).
Allais, L. et al. Chronic cigarette smoke exposure induces microbial and inflammatory shifts and mucin changes in the murine gut. Environ. Microbiol. 18, 1352–1363 (2016).
Benjamin, J. L. et al. Smokers with active Crohn’s disease have a clinically relevant dysbiosis of the gastrointestinal microbiota. Inflamm. Bowel Dis. 18, 1092–1100 (2012).
Opstelten, J. L. et al. Gut microbial diversity is reduced in smokers with Crohn’s disease. Inflamm. Bowel Dis. 22, 2070–2077 (2016).
Leask, A. & Abraham, D. J. TGF-beta signaling and the fibrotic response. FASEB J. 18, 816–827 (2004).
Cosnes, J. Tobacco and IBD: relevance in the understanding of disease mechanisms and clinical practice. Best. Pract. Res. Clin. Gastroenterol. 18, 481–496 (2004).
Liu, P. H. et al. Obesity and weight gain since early adulthood are associated with a lower risk of microscopic colitis. Clin. Gastroenterol. Hepatol. 17, 2523–2532.e1 (2019).
Cotter, T. G., Binder, M., Harper, E. P., Smyrk, T. C. & Pardi, D. S. Optimization of a scoring system to predict microscopic colitis in a cohort of patients with chronic diarrhea. J. Clin. Gastroenterol. 51, 228–234 (2017).
Tworoger, S. S. et al. Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones. J. Nat. Cancer Inst. 97, 595–602 (2005).
Khalili, H. et al. Endogenous levels of circulating androgens and risk of Crohn’s disease and ulcerative colitis among women: a nested case-control study from the nurses’ health study cohorts. Inflamm. Bowel Dis. 21, 1378–1385 (2015).
Liu, P. H. et al. Dietary gluten intake and risk of microscopic colitis among US women without celiac disease: a prospective cohort study. Am. J. Gastroenterol. 114, 127–134 (2019).
Larsson, J. K., Sonestedt, E., Ohlsson, B., Manjer, J. & Sjoberg, K. The association between the intake of specific dietary components and lifestyle factors and microscopic colitis. Eur. J. Clin. Nutr. 70, 1309–1317 (2016).
Khan, M. A., Brunt, E. M., Longo, W. E. & Presti, M. E. Persistent Clostridium difficile colitis: a possible etiology for the development of collagenous colitis. Dig. Dis. Sci. 45, 998–1001 (2000).
Bohr, J., Nordfelth, R., Jarnerot, G. & Tysk, C. Yersinia species in collagenous colitis: a serologic study. Scand. J. Gastroenterol. 37, 711–714 (2002).
Vesoulis, Z., Lozanski, G. & Loiudice, T. Synchronous occurrence of collagenous colitis and pseudomembranous colitis. Can. J. Gastroenterol. 14, 353–358 (2000).
Nielsen, H. L., Dalager-Pedersen, M. & Nielsen, H. High risk of microscopic colitis after Campylobacter concisus infection: population-based cohort study. Gut 69, 1952–1958 (2020).
Fasullo, M. J., Al-Azzawi, Y. & Abergel, J. Microscopic colitis after fecal microbiota transplant. ACG Case Rep. J. 4, e87 (2017).
Tariq, R., Smyrk, T., Pardi, D. S., Tremaine, W. J. & Khanna, S. New-onset microscopic colitis in an ulcerative colitis patient after fecal microbiota transplantation. Am. J. Gastroenterol. 111, 751–752 (2016).
Roth, B., Manjer, J. & Ohlsson, B. Microscopic colitis is associated with several concomitant diseases. Drug Target Insights 7, 19–25 (2013).
Gustafsson, R. J. et al. A cross-sectional study of subclinical and clinical thyroid disorders in women with microscopic colitis compared to controls. Scand. J. Gastroenterol. 48, 1414–1422 (2013).
Thorn, M. et al. Microscopic colitis in Uppsala health region, a population-based prospective study 2005-2009. Scand. J. Gastroenterol. 48, 825–830 (2013).
Ronnblom, A., Holmstrom, T., Tanghoj, H., Wanders, A. & Sjoberg, D. Celiac disease, collagenous sprue and microscopic colitis in IBD. Observations from a population-based cohort of IBD (ICURE). Scand. J. Gastroenterol. 50, 1234–1240 (2015).
Green, P. H. et al. An association between microscopic colitis and celiac disease. Clin. Gastroenterol. Hepatol. 7, 1210–1216 (2009).
Stewart, M., Andrews, C. N., Urbanski, S., Beck, P. L. & Storr, M. The association of coeliac disease and microscopic colitis: a large population-based study. Aliment. Pharmacol. Ther. 33, 1340–1349 (2011).
Sonnenberg, A., Turner, K. O. & Genta, R. M. Associations of microscopic colitis with other lymphocytic disorders of the gastrointestinal tract. Clin. Gastroenterol. Hepatol. 16, 1762–1767 (2018). This study describes the association of MC with coeliac disease and other lymphocytic disorders of the gastrointestinal tract.
Nguyen, G. C., Smalley, W. E., Vege, S. S. & Carrasco-Labra, A., Clinical Guidelines Committee. American Gastroenterological Association Institute guideline on the medical management of microscopic colitis. Gastroenterology 150, 242–246 (2016). This paper describes the American Gastroenterological Association guidelines on the management of MC.
Khalili, H. et al. Microscopic colitis and risk of inflammatory bowel disease in a nationwide cohort study. Gastroenterology 158, 1574–1583.e2 (2020).
Borsotti, E. et al. Low prevalence of colorectal neoplasia in microscopic colitis: a large prospective multi-center study. Dig. Liver Dis. https://doi.org/10.1016/j.dld.2020.09.024 (2020).
Nyboe Andersen, N., Munck, L. K., Hansen, S., Jess, T. & Wildt, S. All-cause and cause-specific mortality in microscopic colitis: a Danish nationwide matched cohort study. Aliment. Pharmacol. Ther. 52, 319–328 (2020).
Bergman, D., Khalili, H., Roelstraete, B. & Ludvigsson, J. F. Microscopic colitis and risk of cancer — a population-based cohort study. J. Crohns Colitis https://doi.org/10.1093/ecco-jcc/jjaa156 (2020).
Westerlind, H. et al. Dense genotyping of immune-related loci identifies HLA variants associated with increased risk of collagenous colitis. Gut 66, 421–428 (2017). The first genetic association study demonstrating the relationship between HLA variants and collagenous colitis.
Goranzon, C. et al. Immunohistochemical characterization of lymphocytes in microscopic colitis. J. Crohns Colitis 7, e434–e442 (2013).
Kumawat, A. K., Strid, H., Tysk, C., Bohr, J. & Hornquist, E. H. Microscopic colitis patients demonstrate a mixed Th17/Tc17 and Th1/Tc1 mucosal cytokine profile. Mol. Immunol. 55, 355–364 (2013). This study is a comprehensive assessment of cytokine profiles observed in MC.
Tagkalidis, P. P., Gibson, P. R. & Bhathal, P. S. Microscopic colitis demonstrates a T helper cell type 1 mucosal cytokine profile. J. Clin. Pathol. 60, 382–387 (2007).
Kumawat, A. K. et al. Microscopic colitis patients have increased proportions of Ki67+ proliferating and CD45RO+ active/memory CD8+ and CD4+8+ mucosal T cells. J. Crohns Colitis 7, 694–705 (2013).
Kumawat, A. K., Elgbratt, K., Tysk, C., Bohr, J. & Hornquist, E. H. Reduced T cell receptor excision circle levels in the colonic mucosa of microscopic colitis patients indicate local proliferation rather than homing of peripheral lymphocytes to the inflamed mucosa. Biomed. Res. Int. 2013, 408638 (2013).
Shibahara, T., Wilcox, J. N., Couse, T. & Madara, J. L. Characterization of epithelial chemoattractants for human intestinal intraepithelial lymphocytes. Gastroenterology 120, 60–70 (2001).
Gunaltay, S. et al. Enhanced levels of chemokines and their receptors in the colon of microscopic colitis patients indicate mixed immune cell recruitment. Med. Inflamm. 2015, 132458 (2015).
Mosnier, J. F. et al. Lymphocytic and collagenous colitis: an immunohistochemical study. Am. J. Gastroenterol. 91, 709–713 (1996).
Munch, A. et al. Dynamics of mucosal permeability and inflammation in collagenous colitis before, during, and after loop ileostomy. Gut 54, 1126–1128 (2005).
Barmeyer, C. et al. Epithelial barrier dysfunction in lymphocytic colitis through cytokine-dependent internalization of claudin-5 and -8. J. Gastroenterol. 52, 1090–1100 (2017).
Munch, A., Soderholm, J. D., Ost, A. & Strom, M. Increased transmucosal uptake of E. coli K12 in collagenous colitis persists after budesonide treatment. Am. J. Gastroenterol. 104, 679–685 (2009). A case report that describes dynamic changes in histological inflammation and mucosal permeability with diversion and restoration of the faecal stream in collagenous colitis.
Farre, R., Fiorani, M., Abdu Rahiman, S. & Matteoli, G. Intestinal permeability, inflammation and the role of nutrients. Nutrients 12, 1185 (2020).
Keita, A. V. et al. Increased uptake of non-pathogenic E. coli via the follicle-associated epithelium in longstanding ileal Crohn’s disease. J. Pathol. 215, 135–144 (2008).
Watson, C. J., Hoare, C. J., Garrod, D. R., Carlson, G. L. & Warhurst, G. Interferon-γ selectively increases epithelial permeability to large molecules by activating different populations of paracellular pores. J. Cell Sci. 118, 5221–5230 (2005).
Schwarz, B. T. et al. LIGHT signals directly to intestinal epithelia to cause barrier dysfunction via cytoskeletal and endocytic mechanisms. Gastroenterology 132, 2383–2394 (2007).
Jarnerot, G., Bohr, J., Tysk, C. & Eriksson, S. Faecal stream diversion in patients with collagenous colitis. Gut 38, 154–155 (1996).
Daferera, N. et al. Fecal stream diversion and mucosal cytokine levels in collagenous colitis: a case report. World J. Gastroenterol. 21, 6065–6071 (2015).
Rindom Krogsgaard, L., Kristian Munck, L., Bytzer, P. & Wildt, S. An altered composition of the microbiome in microscopic colitis is driven towards the composition in healthy controls by treatment with budesonide. Scand. J. Gastroenterol. 54, 446–452 (2019).
Morgan, D. M. et al. Microscopic colitis is characterized by intestinal dysbiosis. Clin. Gastroenterol. Hepatol. 18, 984–986 (2020). This is the most comprehensive study characterizing the microbiome in MC.
Gustafsson, R. J., Ohlsson, B., Benoni, C., Jeppsson, B. & Olsson, C. Mucosa-associated bacteria in two middle-aged women diagnosed with collagenous colitis. World J. Gastroenterol. 18, 1628–1634 (2012).
Fischer, H. et al. Altered microbiota in microscopic colitis. Gut 64, 1185–1186 (2015).
Carstens, A. et al. The gut microbiota in collagenous colitis shares characteristics with inflammatory bowel disease-associated dysbiosis. Clin. Transl Gastroenterol. 10, e00065 (2019).
Millien, V., Rosen, D., Hou, J. & Shah, R. Proinflammatory sulfur-reducing bacteria are more abundant in colonic biopsies of patients with microscopic colitis compared to healthy controls. Dig. Dis. Sci. 64, 432–438 (2019).
Stahl, E. et al. Collagenous colitis is associated with HLA signature and shares genetic risks with other immune-mediated diseases. Gastroenterology 159, 549–561.e8 (2020). This paper is the most comprehensive study of genetics in MC, which highlights shared genetics with other immune-mediated diseases.
Green, H. D. et al. Genome-wide association study of microscopic colitis in the UK biobank confirms immune-related pathogenesis. J. Crohns Colitis 13, 1578–1582 (2019).
Westerlind, H. et al. HLA associations distinguish collagenous from lymphocytic colitis. Am. J. Gastroenterol. 111, 1211–1213 (2016).
Ung, K. A., Gillberg, R., Kilander, A. & Abrahamsson, H. Role of bile acids and bile acid binding agents in patients with collagenous colitis. Gut 46, 170–175 (2000).
Fernandez-Banares, F. et al. Bile acid malabsorption in microscopic colitis and in previously unexplained functional chronic diarrhea. Dig. Dis. Sci. 46, 2231–2238 (2001).
Torres, J. et al. Farnesoid X receptor expression in microscopic colitis: a potential role in disease etiopathogenesis. GE Port. J. Gastroenterol. 25, 30–37 (2018).
Gadaleta, R. M. et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 60, 463–472 (2011).
Mori, S. et al. Proton pump inhibitor induced collagen expression in colonocytes is associated with collagenous colitis. World J. Gastroenterol. 23, 1586–1593 (2017).
Aigner, T. et al. Extracellular matrix composition and gene expression in collagenous colitis. Gastroenterology 113, 136–143 (1997).
Flejou, J. F., Grimaud, J. A., Molas, G., Baviera, E. & Potet, F. Collagenous colitis. Ultrastructural study and collagen immunotyping of four cases. Arch. Pathol. Lab. Med. 108, 977–982 (1984).
Mourelle, M. et al. Stimulation of transforming growth factor beta1 by enteric bacteria in the pathogenesis of rat intestinal fibrosis. Gastroenterology 114, 519–526 (1998).
Gunther, U. et al. Fibrogenesis and fibrolysis in collagenous colitis. Patterns of procollagen types I and IV, matrix-metalloproteinase-1 and -13, and TIMP-1 gene expression. Am. J. Pathol. 155, 493–503 (1999).
Stahle-Backdahl, M. et al. Increased presence of eosinophilic granulocytes expressing transforming growth factor-beta1 in collagenous colitis. Scand. J. Gastroenterol. 35, 742–746 (2000).
Northcutt, M. J., Gentile, N. M., Goldstein, J. L. & Yen, E. F. Bile acid sequestrant therapy in microscopic colitis. J. Clin. Gastroenterol. https://doi.org/10.1097/MCG.0000000000001496 (2021).
Stoicescu, A., Becheanu, G., Dumbrava, M., Gheorghe, C. & Diculescu, M. Microscopic colitis — a missed diagnosis in diarrhea-predominant irritable bowel syndrome. Maedica 7, 3–9 (2012).
Kamp, E. J., Kane, J. S. & Ford, A. C. Irritable bowel syndrome and microscopic colitis: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 14, 659–668.e1 (2016).
Asghar, Z. et al. Diagnostic yield of colonoscopy in patients with symptoms compatible with Rome IV functional bowel disorders. Clin. Gastroenterol. Hepatol. https://doi.org/10.1016/j.cgh.2020.08.062 (2020). This study demonstrated the overlap between Rome IV functional diarrhoeal illnesses and MC.
Hjortswang, H. et al. Defining clinical criteria for clinical remission and disease activity in collagenous colitis. Inflamm. Bowel Dis. 15, 1875–1881 (2009). This paper demonstrates the correlation between disease activity and health-related quality of life using four scoring systems.
Cotter, T. G. et al. Development of a microscopic colitis disease activity index: a prospective cohort study. Gut 67, 441–446 (2018). This study established the first disease activity index for MC as a non-invasive marker for use in clinical trials.
Loreau, J. et al. Long-term natural history of microscopic colitis: a population-based cohort. Clin. Transl Gastroenterol. 10, e00071 (2019).
von Arnim, U., Wex, T., Ganzert, C., Schulz, C. & Malfertheiner, P. Fecal calprotectin: a marker for clinical differentiation of microscopic colitis and irritable bowel syndrome. Clin. Exp. Gastroenterol. 9, 97–103 (2016).
Wildt, S., Nordgaard-Lassen, I., Bendtsen, F. & Rumessen, J. J. Metabolic and inflammatory faecal markers in collagenous colitis. Eur. J. Gastroenterol. Hepatol. 19, 567–574 (2007).
Wagner, M. et al. Increased fecal levels of chromogranin A, chromogranin B, and secretoneurin in collagenous colitis. Inflammation 36, 855–861 (2013).
Wagner, M. et al. Elevated fecal levels of eosinophil granule proteins predict collagenous colitis in patients referred to colonoscopy due to chronic non-bloody diarrhea. Scand. J. Gastroenterol. 51, 835–841 (2016).
Lettesjo, H. et al. Detection of inflammatory markers in stools from patients with irritable bowel syndrome and collagenous colitis. Scand. J. Gastroenterol. 41, 54–59 (2006).
Marlicz, W., Skonieczna-Zydecka, K., Yung, D. E., Loniewski, I. & Koulaouzidis, A. Endoscopic findings and colonic perforation in microscopic colitis: A systematic review. Dig. Liver Dis. 49, 1073–1085 (2017).
Baudet, J. S. & Aguirre-Jaime, A. Factors related to the development of cat scratch colon during colonoscopy. Endoscopy 45, 582–584 (2013).
Shiratori, Y. & Fukuda, K. Collagenous colitis diagnosed by endoscopically induced mucosal tears. BMJ Case Rep. 12, e230570 (2019).
Kakar, S., Pardi, D. S. & Burgart, L. J. Colonic ulcers accompanying collagenous colitis: implication of nonsteroidal anti-inflammatory drugs. Am. J. Gastroenterol. 98, 1834–1837 (2003).
Lazenby, A. J., Yardley, J. H., Giardiello, F. M. & Bayless, T. M. Pitfalls in the diagnosis of collagenous colitis: experience with 75 cases from a registry of collagenous colitis at the Johns Hopkins Hospital. Hum. Pathol. 21, 905–910 (1990).
Magro, F. et al. European consensus on the histopathology of inflammatory bowel disease. J. Crohns Colitis 7, 827–851 (2013).
Robert, M. E. Microscopic colitis: pathologic considerations, changing dogma. J. Clin. Gastroenterol. 38, S18–26 (2004).
Jessurun, J., Yardley, J. H., Giardiello, F. M., Hamilton, S. R. & Bayless, T. M. Chronic colitis with thickening of the subepithelial collagen layer (collagenous colitis): histopathologic findings in 15 patients. Hum. Pathol. 18, 839–848 (1987).
Chetty, R. & Govender, D. Lymphocytic and collagenous colitis: an overview of so-called microscopic colitis. Nat. Rev. Gastroenterol. Hepatol. 9, 209–218 (2012).
Miehlke, S. et al. Microscopic colitis: pathophysiology and clinical management. Lancet Gastroenterol. Hepatol. 4, 305–314 (2019).
Fiehn, A. K. et al. Is revision of cutoff values needed when using CD3 immunohistochemical staining in histopathologic diagnosis of lymphocytic colitis? Hum. Pathol. 84, 115–123 (2019).
Fiehn, A. K. et al. Distribution of histopathological features along the colon in microscopic colitis. Int. J. Colorectal Dis. 36, 151–159 (2021).
Tanaka, M., Mazzoleni, G. & Riddell, R. H. Distribution of collagenous colitis: utility of flexible sigmoidoscopy. Gut 33, 65–70 (1992).
Kanstrup Fiehn, A. M. et al. Topographical distribution of microscopic colitis and the importance of orientation of paraffin-embedded biopsies. Hum. Pathol. 103, 63–71 (2020).
Virine, B., Chande, N. & Driman, D. K. Biopsies from ascending and descending colon are sufficient for diagnosis of microscopic colitis. Clin. Gastroenterol. Hepatol. 18, 2003–2009 (2020).
Fernandez-Banares, F. et al. Current concepts on microscopic colitis: evidence-based statements and recommendations of the Spanish Microscopic Colitis Group. Aliment. Pharmacol. Ther. 43, 400–426 (2016).
American Gastroenterological Association. AGA institute guideline on the management of microscopic colitis: clinical decision support tool. Gastroenterology 150, 276 (2016).
Capurso, G. et al. Lansoprazole-induced microscopic colitis: an increasing problem? Results of a prospecive case-series and systematic review of the literature. Dig. Liver Dis. 43, 380–385 (2011).
Riddell, R. H., Tanaka, M. & Mazzoleni, G. Non-steroidal anti-inflammatory drugs as a possible cause of collagenous colitis: a case-control study. Gut 33, 683–686 (1992).
Edsbacker, S. & Andersson, T. Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn’s disease. Clin. Pharmacokinet. 43, 803–821 (2004).
Miehlke, S. et al. Budesonide is more effective than mesalamine or placebo in short-term treatment of collagenous colitis. Gastroenterology 146, 1222–1230 (2014).
Bonderup, O. K., Hansen, J. B., Teglbjaerg, P. S., Christensen, L. A. & Fallingborg, J. F. Long-term budesonide treatment of collagenous colitis: a randomised, double-blind, placebo-controlled trial. Gut 58, 68–72 (2009).
Miehlke, S. et al. Efficacy and safety of budesonide, vs mesalazine or placebo, as induction therapy for lymphocytic colitis. Gastroenterology 155, 1795–1804 (2018). Randomized controlled trial demonstrating the efficacy and safety of budesonide for the induction of remission for MC and the superiority of budesonide to mesalamine.
Kafil, T. S. et al. Interventions for treating collagenous colitis. Cochrane Database Syst. Rev. 11, CD003575 (2017).
Chande, N. et al. Interventions for treating lymphocytic colitis. Cochrane Database Syst. Rev. 7, CD006096 (2017).
Narla, N. P., Smyrk, T. C., Pardi, D. S. & Tung, J. Clinical features and treatment responses in pediatric lymphocytic and collagenous colitis. J. Pediatr. Gastroenterol. Nutr. 57, 557–561 (2013).
Gentile, N. M. et al. Outcomes of patients with microscopic colitis treated with corticosteroids: a population-based study. Am. J. Gastroenterol. 108, 256–259 (2013).
Miehlke, S. et al. Oral budesonide for maintenance treatment of collagenous colitis: a randomized, double-blind, placebo-controlled trial. Gastroenterology 135, 1510–1516 (2008).
Munch, A. et al. Low-dose budesonide for maintenance of clinical remission in collagenous colitis: a randomised, placebo-controlled, 12-month trial. Gut 65, 47–56 (2016). This is the longest clinical trial demonstrating the efficacy of low-dose budesonide for the maintenance of remission in collagenous colitis.
Reilev, M., Hallas, J., Thomsen Ernst, M., Nielsen, G. L. & Bonderup, O. K. Long-term oral budesonide treatment and risk of osteoporotic fractures in patients with microscopic colitis. Aliment. Pharmacol. Ther. 51, 644–651 (2020).
Wildt, S. et al. Risk of osteoporosis in microscopic colitis. Postgrad. Med. 130, 348–354 (2018).
Kamboj, A. K. et al. Extended-release multimatrix budesonide for microscopic colitis. Inflamm. Bowel Dis. 23, E21–E22 (2017).
Corte, T. et al. Beclomethasone dipropionate in microscopic colitis: results of an exploratory open-label multicentre study (COLCO). United European Gastroenterol. J. 7, 1183–1188 (2019).
Munck, L. K., Kjeldsen, J., Philipsen, E. & Fischer Hansen, B. Incomplete remission with short-term prednisolone treatment in collagenous colitis: a randomized study. Scand. J. Gastroenterol. 38, 606–610 (2003).
El-Matary, W., Girgis, S., Huynh, H., Turner, J. & Diederichs, B. Microscopic colitis in children. Dig. Dis. Sci. 55, 1996–2001 (2010).
Calabrese, C. et al. Mesalazine with or without cholestyramine in the treatment of microscopic colitis: randomized controlled trial. J. Gastroenterol. Hepatol. 22, 809–814 (2007).
Bonderup, O. K. et al. Budesonide treatment of collagenous colitis: a randomised, double blind, placebo controlled trial with morphometric analysis. Gut 52, 248–251 (2003).
Olesen, M., Eriksson, S., Bohr, J., Jarnerot, G. & Tysk, C. Lymphocytic colitis: a retrospective clinical study of 199 Swedish patients. Gut 53, 536–541 (2004).
Jarnerot, G. et al. Familial occurrence of microscopic colitis: a report on five families. Scand. J. Gastroenterol. 36, 959–962 (2001).
Munch, A., Bohr, J., Vigren, L., Tysk, C. & Strom, M. Lack of effect of methotrexate in budesonide-refractory collagenous colitis. Clin. Exp. Gastroenterol. 6, 149–152 (2013).
Munch, A., Fernandez-Banares, F. & Munck, L. K. Azathioprine and mercaptopurine in the management of patients with chronic, active microscopic colitis. Aliment. Pharmacol. Ther. 37, 795–798 (2013).
Riddell, J., Hillman, L., Chiragakis, L. & Clarke, A. Collagenous colitis: oral low-dose methotrexate for patients with difficult symptoms: long-term outcomes. J. Gastroenterol. Hepatol. 22, 1589–1593 (2007).
Vennamaneni, S. R. & Bonner, G. F. Use of azathioprine or 6-mercaptopurine for treatment of steroid-dependent lymphocytic and collagenous colitis. Am. J. Gastroenterol. 96, 2798–2799 (2001).
Pardi, D. S., Loftus, E. V. Jr, Tremaine, W. J. & Sandborn, W. J. Treatment of refractory microscopic colitis with azathioprine and 6-mercaptopurine. Gastroenterology 120, 1483–1484 (2001).
Cotter, T. G. et al. Immune modulator therapy for microscopic colitis in a case series of 73 patients. Aliment. Pharmacol. Ther. 46, 169–174 (2017). The largest case series of thiopurines, methotrexate and TNF antagonists for the management of budesonide-refractory MC.
Pola, S., Fahmy, M., Evans, E., Tipps, A. & Sandborn, W. J. Successful use of infliximab in the treatment of corticosteroid dependent collagenous colitis. Am. J. Gastroenterol. 108, 857–858 (2013).
Anderson, R. J. & Makins, R. Successful use of adalimumab in patient with treatment-refractory microscopic colitis. BMJ Case Rep. 2016, bcr2016215639 (2016).
Munch, A., Ignatova, S. & Strom, M. Adalimumab in budesonide and methotrexate refractory collagenous colitis. Scand. J. Gastroenterol. 47, 59–63 (2012).
Esteve, M. et al. Efficacy of anti-TNF therapies in refractory severe microscopic colitis. J. Crohns Colitis 5, 612–618 (2011).
Jennings, J. J. & Charabaty, A. Vedolizumab-induced remission in 3 patients with refractory microscopic colitis: a tertiary care center case series. Inflamm. Bowel Dis. 25, e97 (2019).
Cushing, K. C., Mino-Kenudson, M., Garber, J., Lochhead, P. & Khalili, H. Vedolizumab as a novel treatment for refractory collagenous colitis: a case report. Am. J. Gastroenterol. 113, 632–633 (2018).
Casper, M., Zimmer, V., Hubschen, U. & Lammert, F. Vedolizumab for refractory collagenous colitis: another piece of the puzzle. Dig. Liver Dis. 50, 1099–1100 (2018).
Riviere, P. et al. Vedolizumab in refractory microscopic colitis: an international case series. J. Crohns Colitis 13, 337–340 (2019).
Bradley, B., Singleton, M. & Lin Wan Po, A. Bismuth toxicity — a reassessment. J. Clin. Pharm. Ther. 14, 423–441 (1989).
Fine, K. D. & Lee, E. L. Efficacy of open-label bismuth subsalicylate for the treatment of microscopic colitis. Gastroenterology 114, 29–36 (1998).
Madisch, A. et al. Boswellia serrata extract for the treatment of collagenous colitis. A double-blind, randomized, placebo-controlled, multicenter trial. Int. J. Colorectal Dis. 22, 1445–1451 (2007).
Cotter, T. G. et al. Case report: pentoxifylline treatment in microscopic colitis. Medicine 96, e8355 (2017).
Wildt, S. et al. Probiotic treatment of collagenous colitis: a randomized, double-blind, placebo-controlled trial with Lactobacillus acidophilus and Bifidobacterium animalis subsp. Lactis. Inflamm. Bowel Dis. 12, 395–401 (2006).
Holster, S. et al. Faecal microbiota transfer in patients with microscopic colitis — a pilot study in collagenous colitis. Scand. J. Gastroenterol. 55, 1454–1466 (2020).
Gunaltay, S., Rademacher, L., Hultgren Hornquist, E. & Bohr, J. Clinical and immunologic effects of faecal microbiota transplantation in a patient with collagenous colitis. World J. Gastroenterol. 23, 1319–1324 (2017).
Irvine, E. J. et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn’s Relapse Prevention Trial Study Group. Gastroenterology 106, 287–296 (1994).
Stjernman, H. et al. Short health scale: a valid, reliable, and responsive instrument for subjective health assessment in Crohn’s disease. Inflamm. Bowel Dis. 14, 47–52 (2008).
Hjortswang, H. et al. The Short Health Scale: a valid measure of subjective health in ulcerative colitis. Scand. J. Gastroenterol. 41, 1196–1203 (2006).
McDermott, E., Keegan, D., Byrne, K., Doherty, G. A. & Mulcahy, H. E. The Short Health Scale: a valid and reliable measure of health related quality of life in English speaking inflammatory bowel disease patients. J. Crohns Colitis 7, 616–621 (2013).
Kane, J. S., Irvine, A. J., Derwa, Y. & Ford, A. C. Fatigue and its associated factors in microscopic colitis. Ther. Adv. Gastroenterol. 11, 1756284818799599 (2018).
Khalili, H. et al. Mortality of patients with microscopic colitis in Sweden. Clin. Gastroenterol. Hepatol. 18, 2491–2499.e3 (2020).
H.K. acknowledges the funding from an American College of Gastroenterology Clinical Research Award and J.F.L. and H.K. acknowledge the National Institutes of Health for funding their research NIA R01 (AG068390).
D.S.P. reports grant funding from Pfizer, Vedanta, Seres, Finch, Applied Molecular Transport and Takeda. J.F.L. coordinates a study on behalf of the Swedish IBD quality register (SWIBREG). This study has received funding from Janssen corporation. H.K. reports grant funding from Takeda and Pfizer and serves as a consultant to Takeda. All other authors declare no competing interests.
Peer review information
Nature Reviews Disease Primers thanks Nilesh Chande, Taku Kobayashi, Stephan Miehlke, Lars Kristian Munck, Ole Nielsen and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- Protopathic bias
Bias that occurs when a treatment given for a disease (outcome) before establishing a formal diagnosis seems to be the cause of the outcome.
- Checkpoint inhibitors
Drugs that promote an antitumour immune response by blocking checkpoint proteins and by stimulating the immune-mediated elimination of tumour cells.
A measure of cumulative cigarette smoking over a lifetime, calculated by multiplying packs of cigarettes per day by years smoked.
- Alpha diversity
The bacterial species richness within a sample.
Pinpoint spots that occur in the intestinal epithelium due to bleeding.
Pain and inflammation of the ball of the foot.
About this article
Cite this article
Burke, K.E., D’Amato, M., Ng, S.C. et al. Microscopic colitis. Nat Rev Dis Primers 7, 39 (2021). https://doi.org/10.1038/s41572-021-00273-2
This article is cited by
Association between frailty and chronic constipation and chronic diarrhea among American older adults: National Health and Nutrition Examination Survey
BMC Geriatrics (2023)
Predominant Antibody Deficiency and Risk of Microscopic Colitis: a Nationwide Case–Control Study in Sweden
Journal of Clinical Immunology (2023)
Colonic bacterial diversity and dysbiosis in active microscopic colitis as compared to chronic diarrhoea and healthy controls: effect of polyethylene glycol after bowel lavage for colonoscopy
BMC Gastroenterology (2022)
Current Treatment Options in Gastroenterology (2022)